Phospholipid composition of postmortem schizophrenic brain by31P NMR spectroscopy

Magnetic Resonance in Medicine

Volumn 61, Issue 1, 2009, Pages 28-34

  Pearce, John M ^a,b   Komoroski, Richard A ^a,b   Mrak, Robert E ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Lysophospholipids; Phosphati dylethanolamine; Phosphatidylcholine; Schizophrenia

Indexed keywords

CELL MEMBRANES; CYTOLOGY; HISTOLOGY; METABOLITES; MULTIVARIANT ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPIDS; TISSUE;

31P-NMR SPECTROSCOPY; LYSOPHOSPHOLIPIDS; MEMBRANE PHOSPHOLIPIDS; MULTIVARIATE ANALYSIS OF VARIANCES; ORGANIC SOLVENT SYSTEM; PHOSPHATI-DYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; SCHIZOPHRENIA;

DISEASES;

2 PROPANOL; HEXANE; ORGANIC SOLVENT; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FRONTAL CORTEX; FRONTAL LOBE; GRAY MATTER; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIPID COMPOSITION; MALE; MENTAL DISEASE; OCCIPITAL LOBE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TEMPORAL LOBE; THROMBOCYTE;

EID: 60349108623     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21820     Document Type: Article

References (43)

1. Horrobin DF, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13:195-207.
2. Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press; 1999. 339 p.
3. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47:8-21.
4. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003; 26:85-102.
5. Ponizovsky AM, Barshtein G, Bergelson LD. Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview. Harv Rev Psychiatry 2003; 11:317-332.
6. Rípová D, Strunecká A, Nemcová V, Farská I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiol Res 1997; 46:59-68.
7. Ponizovsky AM, Modai I, Nechamkin Y, Barshtein G, Ritsner MS, Yedgar S, Lecht S, Bergelson LD. Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. Schizophr Res 2001; 52:121-126.
8. Pangerl AM, Steudle A, Jaroni HW, Rüfer R, Gattaz WF. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol Psychiatry 1991; 30:837-840.
9. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaf-fective disorder. Biol Psychiatry 2003; 53:431-441.
10. Reddy R, Keshavan MS. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia. Prostagland Leukotri Essen Fatty Acids 2003; 69:401-405.
11. 31P magnetic resonance spectroscopy in the assessment of brain phospholipid metabolism in schizophrenia. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Carnforth: Marius Press; 1999. p 45-55.
12. London E, Feigenson GW. Phosphorus NMR analysis of phospholipids in detergents. J Lipid Res 1979; 20:408-412.
13. 31P NMR in the analysis ofextracted tissue phospholipids. In: Quin LD, Verkade JG, editors. Phosphorus-31 NMR spectral properties in compound characterization and structural analysis. New York: VCH; 1994. p 283-294.
14. Lewis DA. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 2002; 26:143-154.
15. 31P nuclear magnetic resonance spectroscopy: a preliminary study. Psychiatry Res Neuroimaging 2001; 106:171-180.
16. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 1998; 55:346-352.
17. 31P NMR spectroscopy of phospholipid metabolites in postmortem schizophrenic brain. Magn Reson Med 2008; 59:469-474.
18. Salzman, S, Endicott J, Clayton P, Winokur G, editors. Diagnostic Evaluation After Death (DEAD). Rockville, MD: NIMH Neurosciences Research Branch; 1983.
19. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnotic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26:57-63.
20. Karson CN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150:455-459.
21. Diagnostic and Statistical Manual of Mental Disorders, 3rd rev. ed. Washington, DC: American Psychiatric Press; 1987.
22. Mirra SS, Heyman A, McKeel D, and participating CERAD neuropathologists. The consortium to establish a registry for Alzheimer's disease (CERAD): Part II. Standardization of the neuropatholgic assessment of Alzheimer's disease. Neurology 1991; 41:479-486.
23. 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol Psychiatry 1997; 42:359-366.
24. 31P NMR spectroscopy. Magn Reson Med 2000; 44:215-223.
25. 31P NMR. Magn Reson Med 1993; 29:724-731.
26. 1H NMR resonance shift standards 85% orthophosphoric acid and tetramethylsilane. Magn Reson Chem 1992; 30:850-854.
27. Malz F, Jancke H. Validation of quantitative NMR. J Pharmaceut Biomed Anal 2005; 38:813-823.
28. Mahadik SP, Mukherjee S, Correnti EE, Kelkar HS, Wakade CG, Costa RM, Scheffer R. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophrenia Res 1994; 13:239-247.
29. Ryazantseva NV, Novitskii VV, Kublinsaya MM. Changes in the lipid phase of erythrocyte membranes in patients with paranoid schizophrenia. Bull Exp Biol Med 2002; 1:84-86.
30. Keshavan MS, Mallinger A, Panchalingam KS, Pettegrew JW. Erythrocyte membrane phospholipid alterations in schizophrenia. Biol Psychiatry 1992; 31:62A-63A.
31. Demish L, Heinz K, Gerbaldo H, Kirsten R. Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Prostaglan Leukotri Essen Fatty Acids 1992; 46:47-52.
32. Yao JK, Yasaei P, van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglan Leukotri Essen Fatty Acids 1992; 46:39-46.
33. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Res 2000; 42:7-17.
34. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 2004; 56:41-45.
35. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 1995; 16:1-6.
36. Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. Increased phospholipase A2 activity in schizophrenia with absent resonse to niacin. Schizophr Res 2003; 61:1-6.
37. Berman KF, Weinberger DR. Neuroimaging studies of schizophrenia. In: Charney DS, NestlerEJ, Bunney BS, editors. Neurobiology ofmental illness. Oxford: Oxford University Press; 1999. p 246-257.
38. Dean CE. Antipsychotic-associate neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30:174-189.
39. Schmitt A, Maras A, Petroianu G, Braus DF, Scheuer L, Gattaz WF. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. J Neural Transm 2001; 108:1081-1091.
40. Levant B, Crane JF, Carlson SE. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30:728-732.
41. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KRR. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12:934-945.
42. O'Brien JS, Sampson EL. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res 1965; 6:537-551.
43. 31P NMR spectroscopy in phospholipid research. Future Lipidology 2006; 1:115-125.